ISRCTN79831382已完成未知
Does Adjuvant Zoledronic acid redUce REcurrence in patients with high risk localised breast cancer?
The University of Sheffield (UK)0 个研究点目标入组 3,360 人开始时间: 2003年8月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 3,360
研究概览
简要总结
2011 Results article in http://www.ncbi.nlm.nih.gov/pubmed/21394500 safety and tolerability results 2011 Results article in http://www.ncbi.nlm.nih.gov/pubmed/21995387 results 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34026478/ ten-year follow-up results (added 25/05/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Patients with stage II or III primary breast cancer
- •1. Female patients with Stage II/III primary breast cancer, with T stage =T1
- •2. Patients should be receiving/scheduled to receive chemotherapy and/or endocrine therapy
- •3. Patients receiving neo-adjuvant therapy
- •a. Must have tumour size of >5 cm (T3), features of locally advanced disease (T4) or biopsy-proven lymph node involvement
- •b. Should be scheduled to proceed to definitive surgery$ and/or radical radiotherapy with curative intent within 6 months of starting neoadjuvant therapy
- •c. Time between commencement of neoadjuvant treatment and planned start date of study drug should be =30 days
- •4. Patients receiving adjuvant therapy
- •a. Must have undergone complete primary tumour resection and treatment of the axillary lymph nodes*, without any prior neoadjuvant therapy#
- •b. Must have evidence of lymph node involvement
- •c. Time between definitive surgery and planned start date of study drug should be =60 days
- •5. Performance status: Karnofsky Index =80% or Eastern Cooperative Oncology Group (ECOG) 0 and 1
- •6. Women of childbearing potential must be using a reliable and appropriate method of contraception
- •7. Age =18 years
- •8. Patient must have given written informed consent prior to any study-specific procedures
- •$Final definitive surgery is considered to include re-operation for inadequate margins or another bona fide oncological indication
- •*Patients whose treatment plan is to proceed to further primary tumour resection and/or treatment of the axillary lymph nodes (e.g. clearance or radiotherapy) with curative intent after completion of chemotherapy would be eligible but this must be completed within 9 months of randomisation
- •#Pre-operative endocrine therapy of less than 30 days would not be classed as prior neoadjuvant therapy
排除标准
- •1. Metastatic or recurrent breast cancer or a history of breast cancer (aside from ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS]) prior to the currently diagnosed case
- •2. History of prior cancers within the preceding 5 years (including previous contralateral breast cancer), aside from non-melanomatous skin cancer or carcinoma in situ of the uterine cervix treated with curative intent
- •3. History of diseases with influence on bone metabolism, such as Paget?s disease of bone, primary hyperparathyroidism or osteoporosis requiring treatment at the time of study entry or considered likely to become necessary within the subsequent 6 months
- •4. Severe physical or psychological concomitant diseases that might impair compliance with the provisions of the study protocol
- •5. Prior treatment with bisphosphonates within the past year
- •6. Serum creatinine >1.5 x Upper Limit of Normal
- •7. Known hypersensitivity to bisphosphonates
- •8. Current active dental problems including dental abscess or infection of the jawbone (maxilla or mandible), or a current or prior diagnosis of osteonecrosis of the jaw (ONJ)
- •9. Recent (within 4 weeks of study entry) or planned dental or jaw surgery (e.g. extractions, implants). Recent dental fillings, teeth scaling and polishing or minor gingival surgery do not exclude the patient.
- •10. Pregnancy or breast-feeding
- •11. Use of other investigational drugs in the 30 days prior to study entry. (Patients may be receiving treatments within a clinical trial providing the treatment under test has a licensed indication within your country).
研究者
相似试验
进行中（未招募）
3 期
AZURE BR 2-03 - Adjuvant Zoledronic acid in patients with high risk localised breast cancer.ACTRN12606000293561Prof Robert Coleman, The University of Sheffield, United Kingdom3,300
Unknown
3 期
Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast CancerMetastatic CancerBreast CancerNCT00072020University of Sheffield
已完成
3 期
Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral HeadAvascular Necrosis of Femoral HeadNCT00939900Seoul National University Bundang Hospital110
尚未招募
2 期
Effect of addition of zoledronic acid to chemotherapy in improving the response of tumor before surgery, in women with breast cancer (triple negative subtype)CTRI/2019/09/021060Intramural fund of JIPMER
已完成
3 期
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip FractureOsteoporosisHip FractureNCT00046254Novartis Pharmaceuticals2,127